Literature DB >> 6109326

Beta-lactamase inactivation by mechanism-based reagents.

J Fisher, J G Belasco, R L Charnas, S Khosla, J R Knowles.   

Abstract

The mechanistic pathway followed by the E. coli RTEM beta-lactamase has been studied with a view to clarifying the mode of action of a number of recently discovered inactivators of the enzyme. There is clear evidence that the beta-lactamase-catalysed hydrolysis of the 7-alpha-methoxycephem, cefoxitin, proceeds via an acyl-enzyme intermediate. An analysis of the inactivation reactions of all the known beta-lactam derivatives that result in irreversible loss of enzyme activity permits the identification of three structural features required for a beta-lactamase inactivator. The application of these principles suggests a new group of mechanism-based inactivators of the enzyme: the sulphones of N-acyl derivatives of 6-beta-aminopenicillanic acid that are themselves poor substrates for the enzyme. These sulphones are powerful inactivators of the beta-lactamase.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6109326     DOI: 10.1098/rstb.1980.0048

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN: 0962-8436            Impact factor:   6.237


  16 in total

1.  Rational design of a beta-lactamase inhibitor achieved via stabilization of the trans-enamine intermediate: 1.28 A crystal structure of wt SHV-1 complex with a penam sulfone.

Authors:  Pius S Padayatti; Anjaneyulu Sheri; Monica A Totir; Marion S Helfand; Marianne P Carey; Vernon E Anderson; Paul R Carey; Christopher R Bethel; Robert A Bonomo; John D Buynak; Focco van den Akker
Journal:  J Am Chem Soc       Date:  2006-10-11       Impact factor: 15.419

2.  Single-turnover and steady-state kinetics of hydrolysis of cephalosporins by beta-lactamase I from Bacillus cereus.

Authors:  R Bicknell; S G Waley
Journal:  Biochem J       Date:  1985-10-01       Impact factor: 3.857

3.  Effect of the inhibitor-resistant M69V substitution on the structures and populations of trans-enamine beta-lactamase intermediates.

Authors:  Monica A Totir; Pius S Padayatti; Marion S Helfand; Marianne P Carey; Robert A Bonomo; Paul R Carey; Focco van den Akker
Journal:  Biochemistry       Date:  2006-10-03       Impact factor: 3.162

Review 4.  Evolution of beta-lactamase inhibitors.

Authors:  D M Livermore
Journal:  Intensive Care Med       Date:  1994-07       Impact factor: 17.440

5.  Novel carbapenem derivative SF2103A: studies on the mode of beta-lactamase inactivation.

Authors:  A Yamaguchi; T Hirata; T Sawai
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

6.  Interaction of beta-iodopenicillanate with the beta-lactamases of Streptomyces albus G and Actinomadura R39.

Authors:  J M Frère; C Dormans; C Duyckaerts; J De Graeve
Journal:  Biochem J       Date:  1982-12-01       Impact factor: 3.857

7.  The exocellular beta-lactamase of Streptomyces albus G. Purification, properties and comparison with the exocellular DD-carboxypeptidase.

Authors:  C Duez; J M Frère; D Klein; M Noël; J M Ghuysen; L Delcambe; L Dierickx
Journal:  Biochem J       Date:  1981-01-01       Impact factor: 3.857

Review 8.  Three decades of beta-lactamase inhibitors.

Authors:  Sarah M Drawz; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

9.  Interaction between non-classical beta-lactam compounds and the Zn2+-containing G and serine R61 and R39 D-alanyl-D-alanine peptidases.

Authors:  J A Kelly; J M Frère; D Klein; J M Ghuysen
Journal:  Biochem J       Date:  1981-10-01       Impact factor: 3.857

10.  Structural basis of the inhibition of class A beta-lactamases and penicillin-binding proteins by 6-beta-iodopenicillanate.

Authors:  Eric Sauvage; Astrid Zervosen; Georges Dive; Raphael Herman; Ana Amoroso; Bernard Joris; Eveline Fonzé; Rex F Pratt; André Luxen; Paulette Charlier; Frédéric Kerff
Journal:  J Am Chem Soc       Date:  2009-10-28       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.